News

As per the agreement, TB Alliance and AstraZeneca are expected to contribute TB drug discovery projects into a joint portfolio that will be co-developed by both parties. Sharing

Under the terms of the agreement, Warnex has obtained the rights to establish a laboratory-developed test for Septin9 and offer colorectal cancer blood testing services in Canada. Warnex

As consideration for this undertaking, Pillar5 has issued to IntelGenx 114 voting common shares of Pillar5, representing 10% of the issued and outstanding shares of Pillar5. The shares

The milestone payment is part of an exclusive commercial licensing agreement for Ceplene with Meda in Europe and certain Pacific Rim countries signed by the two companies in

GlycoVaxyn said that using its proprietary technology, staphylococcal surface polysaccharides will be conjugated in-vivo to conserved protein antigens from S aureus. The efficacy of this new bioconjugate vaccine

As per the agreement, BioSeek is expected to apply its proprietary BioMAP platform to advance Eisai’s multiple discovery projects in the oncology and inflammation areas. The agreement encompasses

FMC has posted a net income of $80.4m for the first quarter of 2010, compared to $70.9m, for the prior year period. Income from operations was $135.9m, compared

Both the entities said that on April 22, 2010 at joint advisory committee meeting, FDA questioned the effectiveness of niacin included in the current Acurox formulation but cited

In an oral presentation at Digestive Disease Week (DDW) in New Orleans, Gary Lichtenstein, professor of medicine and director of the inflammatory bowel disease program at the Hospital